Compare GFL Environmental Inc. Subordinate voting shares no par value (GFL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GFL Environmental Inc. Subordinate voting shares no par value vs Spyre Therapeutics Inc. Common Stock — how do they compare? GFL Environmental Inc. Subordinate voting shares no par value trades at $43.02 (market cap $18.64B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: GFL Environmental Inc. Subordinate voting shares no par value is far larger — about 2.5× Spyre Therapeutics Inc. Common Stock's market cap, and GFL Environmental Inc. Subordinate voting shares no par value pays a 0.16% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GFL Environmental Inc. Subordinate voting shares no par value for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GFL | SYRE | |
|---|---|---|
Market Cap | $18.64B | $7.52B |
Volume | 2,514,524 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $46.51 | $108.92 |
52-Week Low | $33.54 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $25.61B | $6.52B |
Dividend Yield | 0.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GFL trades at $42.75, up 0.87% today, with a bullish technical signal from moving averages. Recent Q2 2026 earnings missed estimates, but the company raised full-year 2026 guidance. Revenue is projected to grow to $7.0B in 2026, though net income is expected to turn negative. The company recently acquired SECURE Waste Infrastructure and announced a quarterly dividend, signaling financial activity.
Outlook is mixed: strong analyst buy consensus (77.8%) and positive news flow support upside, but negative profit margins and high valuation ratios pose risks. The stock's performance hinges on execution of growth initiatives and margin improvement in a competitive industrial sector.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.
Read more on GFL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
